260 related articles for article (PubMed ID: 35438790)
1. Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan.
Ito S; Hataya H; Ashida A; Hamada R; Ishikawa T; Ishikawa Y; Shimono A; Konomoto T; Miyazawa T; Ogura M; Tanaka K; Kagami S
Nephrol Dial Transplant; 2023 Feb; 38(2):414-424. PubMed ID: 35438790
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance.
Maruyama S; Ikeda Y; Kaname S; Kato N; Matsumoto M; Ishikawa Y; Shimono A; Miyakawa Y; Nangaku M; Shibagaki Y; Okada H
J Nephrol; 2024 May; ():. PubMed ID: 38809358
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance.
Ito S; Saito A; Sakurai A; Watanabe K; Karakawa S; Miyamura T; Yokosuka T; Ueki H; Goto H; Yagasaki H; Kinoshita M; Ozeki M; Yokoyama N; Teranishi H
Bone Marrow Transplant; 2024 Mar; 59(3):315-324. PubMed ID: 38102212
[TBL] [Abstract][Full Text] [Related]
7. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab in secondary atypical haemolytic uraemic syndrome.
Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
Gäckler A; Schönermarck U; Dobronravov V; La Manna G; Denker A; Liu P; Vinogradova M; Yoon SS; Praga M
BMC Nephrol; 2021 Jan; 22(1):5. PubMed ID: 33407224
[TBL] [Abstract][Full Text] [Related]
10. Interventions for atypical haemolytic uraemic syndrome.
Pugh D; O'Sullivan ED; Duthie FA; Masson P; Kavanagh D
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012862. PubMed ID: 33783815
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
[TBL] [Abstract][Full Text] [Related]
12. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
13. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
[TBL] [Abstract][Full Text] [Related]
14. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
Nga HS; Palma LMP; Ernandes Neto M; Fernandes-Charpiot IMM; Garcia VD; Kist R; Miranda SMC; Macedo de Souza PA; Pereira GM; de Andrade LGM
PLoS One; 2021; 16(11):e0258319. PubMed ID: 34748552
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab in paediatric atypical haemolytic uraemic syndrome: Lessons learned from a single-centre experience in the United Arab Emirates.
Kumar G; Al-Masri O; Alismaili Z; Tawfik E; Al-Ghabra MK; Ilyas SH; Al-Khasawneh E
J Paediatr Child Health; 2019 Oct; 55(10):1237-1240. PubMed ID: 30714243
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.
Legendre CM; Campistol JM; Feldkamp T; Remuzzi G; Kincaid JF; Lommelé Å; Wang J; Weekers LE; Sheerin NS
Transpl Int; 2017 Dec; 30(12):1275-1283. PubMed ID: 28801959
[TBL] [Abstract][Full Text] [Related]
18. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Ariceta G; Dixon BP; Kim SH; Kapur G; Mauch T; Ortiz S; Vallee M; Denker AE; Kang HG; Greenbaum LA;
Kidney Int; 2021 Jul; 100(1):225-237. PubMed ID: 33307104
[TBL] [Abstract][Full Text] [Related]
19. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E; Scully M; Ariceta G; Barbour T; Cataland S; Heyne N; Miyakawa Y; Ortiz S; Swenson E; Vallee M; Yoon SS; Kavanagh D; Haller H;
Kidney Int; 2020 Jun; 97(6):1287-1296. PubMed ID: 32299680
[TBL] [Abstract][Full Text] [Related]
20. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
Walle JV; Delmas Y; Ardissino G; Wang J; Kincaid JF; Haller H
J Nephrol; 2017 Feb; 30(1):127-134. PubMed ID: 26995002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]